1DHR Stock Chart & Stats
€186.10
€2.35(1.41%)
At close: 4:00 PM EDT
€186.10
€2.35(1.41%)
Day’s Range― - ―
52-Week Range€93.00 - €308.00
Previous CloseN/A
Volume176.00
Average Volume (3M)15.00
Market Cap
€145.80B
Enterprise Value€180.78B
Total Cash (Recent Filing)€5.68B
Total Debt (Recent Filing)€26.48B
Price to Earnings (P/E)37.9
Beta0.42
Next Earnings
Jan 27, 2027EPS Estimate
2.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.12
Shares Outstanding703,530,800
10 Day Avg. Volume21
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio-9.26
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€230.36Price Target Upside23.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)7.68
Revenue Forecast (FY)€23.51B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationDanaher’s substantial operating and free cash flow provides internal funding for innovation, acquisitions, debt service, and shareholder returns. Strong conversion of earnings into cash also supports resilience through cyclical laboratory and bioprocessing demand, while reducing reliance on external financing.
Recurring Consumables And Services ModelDanaher combines instruments with recurring consumables, reagents, software, and aftermarket services. This installed-base model deepens customer relationships, creates repeat purchasing, and can make revenue more durable than a business dependent only on episodic capital-equipment sales.
AI And Automation Platform ExpansionThe autonomous-lab initiative broadens Danaher’s role from selling individual tools to enabling integrated research workflows. Combining instruments, consumables, robotics, software, and AI could improve customer productivity, increase platform pull-through, and create durable differentiation in scientific automation.
Bears Say
Respiratory Revenue VolatilityRespiratory exposure remains a meaningful source of revenue volatility because demand is influenced by infection rates and flu-season variability. Continued weakness can suppress Diagnostics growth and make consolidated performance less representative of underlying trends in other businesses.
Modest Growth And Lower ProfitabilityRecent growth has not fully reflected the portfolio’s potential, and profitability remains below prior peak levels. A slower revenue trajectory can limit operating leverage, while the margin reset reduces earnings cushion and makes sustained acceleration more important to future performance.
Higher Leverage Reduces FlexibilityHigher leverage leaves Danaher with less financial flexibility than in prior years, even though equity remains substantial. Additional debt can increase interest and refinancing exposure, constrain acquisition capacity, and reduce room to respond aggressively if end-market conditions weaken.
Danaher News
1DHR FAQ
What was Danaher Corp.’s price range in the past 12 months?
Danaher Corp. lowest stock price was €93.00 and its highest was €308.00 in the past 12 months.
What is Danaher Corp.’s market cap?
Danaher Corp.’s market cap is €145.80B.
When is Danaher Corp.’s upcoming earnings report date?
Danaher Corp.’s upcoming earnings report date is Jan 27, 2027 which is in 87 days.
How were Danaher Corp.’s earnings last quarter?
Danaher Corp. released its earnings results on Oct 21, 2026. The company reported €1.889 earnings per share for the quarter, beating the consensus estimate of €1.716 by €0.173.
Is Danaher Corp. overvalued?
According to Wall Street analysts Danaher Corp.’s price is currently Undervalued.
Does Danaher Corp. pay dividends?
Danaher Corp. does not currently pay dividends.
What is Danaher Corp.’s EPS estimate?
Danaher Corp.’s EPS estimate is 2.22.
How many shares outstanding does Danaher Corp. have?
Danaher Corp. has 703,530,800 shares outstanding.
What happened to Danaher Corp.’s price movement after its last earnings report?
Danaher Corp. reported an EPS of €1.889 in its last earnings report, beating expectations of €1.716. Following the earnings report the stock price went up 3.698%.
Which hedge fund is a major shareholder of Danaher Corp.?
Currently, no hedge funds are holding shares in IT:1DHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Danaher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€230.36 (23.78% Upside)
€230.36 (23.78% Upside)
Blogger Sentiment
Bullish
IT:1DHR Sentiment 64%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €11.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.78%
12-Months-Change
Fundamentals
Return on Equity
8.18%
Trailing 12-Months
Asset Growth
16.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Danaher Corp.
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
1DHR Company Deck
1DHR Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive. Danaher delivered better-than-expected revenue, earnings, margins, and cash flow; raised full-year EPS guidance; reported improving trends across biotechnology, life sciences, and diagnostics; and highlighted strong orders, AI initiatives, and acquisition integration. The main challenges were respiratory-related revenue declines, North American weakness, academic and selected discovery-market softness, and a measured 4%-5% initial 2027 growth framework. Highlights significantly outweighed the lowlights.View all IT:1DHR earnings summaries1DHR Revenue Breakdown
29.68% Biotechnology
29.85% Life Sciences
40.46% Diagnostics

1DHR Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€230.36
▲(23.78% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










